| oxaliplatin / Generic mfg. |
| Completed | 2b | 198 | US, Europe, RoW | Sorafenib (Nexavar, BAY43-9006) + mFOLFOX6 (5-FU, levo-leucovorin, oxaliplatin), Matching placebo + mFOLFOX6 (5-FU, levo-leucovorin, oxaliplatin) | Bayer, Amgen | Metastatic Colorectal Cancer | 01/11 | 02/12 | | |
|
| Terminated | 2b | 191 | Japan, US, Europe | sunitinib, Sutent, SU011248, mFOLFOX6, bevacizumab, Avastin | Pfizer | Colorectal Neoplasms | 07/11 | 07/11 | | |
NCT00016198: Fluorouracil and Leucovorin With or Without Oxaliplatin in Treating Patients With Recurrent Metastatic Colorectal Cancer |
|
|
| Completed | 2 | | US | FOLFOX regimen, fluorouracil, leucovorin calcium, oxaliplatin | Prologue Research International | Colorectal Cancer | 04/03 | 12/10 | | |
NCT00017082: Oxaliplatin in Treating Patients With Recurrent Metastatic Colorectal Cancer |
|
|
| Completed | 2 | | US | oxaliplatin | Prologue Research International | Colorectal Cancer | 06/03 | 12/10 | | |
NCT00044343: GW572016, An Oral Drug For Colorectal Cancer Patients Having Prior Therapy With 5-FU Plus CPT-11 And/Or Oxaliplatin |
|
|
| Completed | 2 | 80 | US, Canada | lapatinib | GlaxoSmithKline | Colorectal Cancer | 10/03 | 10/03 | | |
NCT00065117: Safety, Tolerability and Efficacy of ZD6126 in Combination With Oxaliplatin, 5-Fluorouracil and Leucovorin in Subjects With Metastatic Colorectal Cancer. |
|
|
| Terminated | 2 | 180 | US | ZD6126, Placebo, 5-fluorouracil, leucovorin, oxaliplatin | AstraZeneca | Colorectal Neoplasms, Metastases, Neoplasm | 02/04 | 02/04 | | |
NCT00399750: TREE-2: Three Regimens of Eloxatin in Advanced Colorectal Cancer |
|
|
| Completed | 2 | 373 | US | oxaliplatin, fluoropyrimidine, bevacizumab | Sanofi | Colorectal Cancer | | 06/05 | | |
| Completed | 2 | 20 | RoW | Oxaliplatin | Sanofi | Stomach Neoplasms | 07/06 | 07/06 | | |
NCT00123851: Tarceva, Capecitabine and Oxaliplatin for Metastatic Colorectal Cancer |
|
|
| Completed | 2 | 32 | US | Tarceva (OSI-774), Capecitabine, Oxaliplatin | Dana-Farber Cancer Institute, Sanofi-Synthelabo, OSI Pharmaceuticals, Hoffmann-La Roche, Genentech, Inc., Massachusetts General Hospital, Beth Israel Deaconess Medical Center | Colorectal Cancer, Neoplasm Metastasis | 08/06 | 08/06 | | |
NCT00142467: Gemcitabine, Oxaliplatin in Combination With Bevacizumab in Patients With Hepatocellular Carcinoma |
|
|
| Completed | 2 | 33 | US | Gemcitabine, Gemzar, Oxaliplatin, Eloxatin, Bevacizumab, Avastin | Massachusetts General Hospital, Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center, Brigham and Women's Hospital, Genentech, Inc., Sanofi-Synthelabo, Eli Lilly and Company | Hepatocellular Carcinoma | 08/06 | 06/11 | | |
NCT02694718: A Study of Capecitabine Plus Oxaliplatin in Combination With Pre-operative Pelvic Radiotherapy in Rectal Cancer |
|
|
| Completed | 2 | 60 | Europe | Capecitabine, Xeloda, Ro09-1978, Oxaliplatin, Eloxatin | Hoffmann-La Roche, Sanofi-Synthélabo (Schweiz) AG | Rectal Cancer | 08/06 | 11/06 | | |
| Completed | 2 | 67 | Europe | oxaliplatin | Sanofi | Biliary Tract Neoplasms | 09/06 | 09/06 | | |
NCT00280618: Oxaliplatin in Unresectable Hepatocellular Carcinoma |
|
|
| Completed | 2 | | RoW | Oxaliplatin | Sanofi | Carcinoma, Hepatocellular | 11/06 | | | |
NCT00254137: Cap/Iri Plus Cetuximab Compared to Cap/ox Plus Cetuximab in Patients With Metastatic Colorectal Cancer. |
|
|
| Completed | 2 | 92 | Europe | capecitabine, irinotecan, oxaliplatin, cetuximab | Ludwig-Maximilians - University of Munich, Merck Sharp & Dohme LLC, Sanofi, Pfizer, Hoffmann-La Roche | Metastatic Colorectal Cancer | | 11/06 | | |
NCT00256269: Oxaliplatin and Irinotecan in Recurrent or Metastatic Esophageal and Gastroesophageal (GE) Junction Carcinoma |
|
|
| Terminated | 2 | 4 | US | Oxaliplatin, Irinotecan | University of California, Irvine, Sanofi | Esophageal Cancer, Gastroesophageal Cancer | 02/07 | 02/07 | | |
PROCTFUL, NCT00263029: Preoperative Radiotherapy/ Oxaliplatin/ Capecitabine Treatment For Unresectable Locally-advanced Rectal Cancer |
|
|
| Completed | 2 | 18 | RoW | Oxaliplatin, Capecitabine, Radiotherapy | Sanofi | Rectal Neoplasms | 03/07 | | | |
NCT00083616: Evaluating Panitumumab (ABX-EGF) Monotherapy in Patients With Metastatic Colorectal Cancer Following Treatment With Fluoropyrimidine, Irinotecan, and Oxaliplatin Chemotherapy |
|
|
| Completed | 2 | 185 | US | Panitumumab, ABX-EGF, Vectibix | Amgen | Colorectal Cancer, Metastatic Cancer | 05/07 | 12/08 | | |
NCT00215982: Study of Capecitabine With Irinotecan and Oxaliplatin (Eloxatin) in Advanced Colorectal Cancer |
|
|
| Completed | 2 | 24 | US | capecitabine, XELODA™, Oxaliplatin, E LOXATIN™, Irinotecan, CAMPTOSAR™ | H. Lee Moffitt Cancer Center and Research Institute, Roche Pharma AG | Colorectal Cancer | 07/07 | 07/07 | | |
NCT00094965: Oxaliplatin With FOLFOX4 in Patients With Normal and Abnormal Renal Function |
|
|
| Completed | 2 | 43 | US | Oxaliplatin (SR96669) | Sanofi | Gastrointestinal Cancer | 08/07 | 08/07 | | |
NCT00192075: A Randomized Trial of Avastin + Gemcitabine + 5-Fluorouracil (5FU)/Folinic Acid Versus Avastin + Oxaliplatin + 5FU/Folinic Acid in Metastatic Colorectal Cancer |
|
|
| Completed | 2 | 84 | US | Gemcitabine, Gemzar, avastin, 5FU/folinic acid, oxaliplatin | Eli Lilly and Company | Colorectal Cancer | | 11/07 | | |
NCT00174616: CORE: Capecitabine, Oxaliplatin, Radiotherapy and Excision |
|
|
| Completed | 2 | 87 | Europe | Oxaliplatin, capecitabine, radiotherapy | Sanofi | Rectal Neoplasms | 11/07 | 11/07 | | |
| Completed | 2 | 215 | Canada, Europe | AZD2171, cediranib, RECENTIN™, 5-fluorouracil, 5-FU, Leucovorin, Oxaliplatin, Eloxatin®, Bevacizumab, Avastin® | AstraZeneca | Colorectal Cancer | 11/07 | 10/09 | | |
NCT00454116 / 2006-005023-42: A Phase II, Double Blind Study of 2 Doses of ZACTIMA™(ZD6474) in Combination With FOLFIRI vs FOLFIRI Alone for the Treatment of Colorectal Cancer in Patients |
|
|
| Completed | 2 | 106 | US, Europe, RoW | Vandetanib, ZD6474, ZACTIMA™, FOLFIRI | Genzyme, a Sanofi Company | Colorectal Cancer | 03/08 | 11/09 | | |
NCT00500292 / 2006-005022-23: A Phase II Study of 2 Doses of ZD6474 (Vandetanib) in Combination With FOLFOX vs FOLFOX Alone for the Treatment of Colorectal Cancer |
|
|
| Completed | 2 | 109 | Europe, RoW | Vandetanib, AZ6474, ZACTIMA™, SAR390530, FOLFOX regimen=oxaliplatin, fluorouracil, & folinic acid | Genzyme, a Sanofi Company | Colorectal, Cancer | 03/08 | 11/16 | | |
NCT00408772: Oxaliplatin, Capecitabine, and Bevacizumab Followed By Surgery and/or Radiofrequency Ablation in Patients With Colorectal Cancer |
|
|
| Withdrawn | 2 | 0 | US | bevacizumab, capecitabine, oxaliplatin, conventional surgery, neoadjuvant therapy, radiofrequency ablation | University of California, Davis, Sanofi | Colorectal Cancer, Metastatic Cancer | 04/08 | 04/08 | | |
NCT00259402: Oxaliplatin in Esophagus Cancer (Advanced) 1st Line |
|
|
| Completed | 2 | 41 | Europe | Oxaliplatin + cisplatin + 5-Fluorouracil (5-FU) | Sanofi | Esophageal Neoplasms | 10/08 | 10/08 | | |
NCT00345696 / 2005-006171-12: 1stline Study Capecitabine Administered on Continuous Way Plus Oxaliplatin&Bevacizumab Every 2weeks in Metastatic CCR. |
|
|
| Completed | 2 | 32 | Europe | Bevacizumab, Avastin, Capecitabine, Xeloda, Oxaliplatine, Eloxatin | Unidad Integral de Investigación en Oncología S.L., Hoffmann-La Roche | Metastatic Colorectal Cancer | 10/08 | 01/11 | | |
| Completed | 2 | 136 | Europe | FOLFOX-4+cetuximab, FOLFOX-4 | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD), Merck Sharp & Dohme LLC | Colorectal Cancer | 02/09 | 02/09 | | |
NCT00361231: Gemcitabine, Oxaliplatin in Combination With Bevacizumab in Biliary Tract and Gallbladder Cancer |
|
|
| Completed | 2 | 35 | US | Bevacizumab, Avastin, Gemcitabine, Gemzar, Oxaliplatin, Eloxatin | Massachusetts General Hospital, Genentech, Inc., Sanofi, Beth Israel Deaconess Medical Center, Brigham and Women's Hospital, Dana-Farber Cancer Institute | Biliary Tract Cancer, Gallbladder Adenocarcinoma | 03/09 | 08/12 | | |
NCT00419159 / 2006-003255-20: Efficacy and Safety of Everolimus in Patients With Metastatic Colorectal Cancer Who Have Failed Prior Targeted Therapy and Chemotherapy |
|
|
| Completed | 2 | 199 | US | Everolimus (RAD001), Afinitor, Zortress, Certican | Novartis Pharmaceuticals | Colorectal Cancer | 03/09 | 03/09 | | |
NCT00642603: A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer |
|
|
| Terminated | 2 | 41 | US | capecitabine [Xeloda], bevacizumab [Avastin], oxaliplatin, irinotecan | Hoffmann-La Roche | Colorectal Cancer | 03/09 | 03/09 | | |
NCT00118755: A Study of Two Different Schedules of Xeloda (Capecitabine) as First Line Therapy in Patients With Metastatic Colorectal Cancer |
|
|
| Completed | 2 | 435 | US | capecitabine, Oxaliplatin, bevacizumab | Hoffmann-La Roche | Colorectal Cancer | 04/09 | | | |
NCT00531115 / 2006-007062-11: Phase II Study to Evaluate Safety and Efficacy of Cetuximab in Combination With XELOX for 12 Weeks Followed by Maintenance Treatment With Cetuximab Plus Capecitabine as First-line Treatment in Elderly Patients With Metastatic Colorectal Cancer. |
|
|
| Terminated | 2 | 28 | Europe | cetuximab 5mg/ml | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD), Merck Sharp & Dohme LLC | Metastatic Colorectal Cancer | 04/09 | 04/09 | | |
NCT00338988: Oxaliplatin and Capecitabine in Patients With Unresectable Cholangiocarcinoma |
|
|
| Completed | 2 | 44 | US | Capecitabine, Xeloda, Oxaliplatin, Eloxatin | M.D. Anderson Cancer Center, Sanofi-Synthelabo | Cancer of the Gallbladder, Cancer of the Biliary Tract | 05/09 | 05/09 | | |
XELOX-A-DVS, NCT00159432: Study of Oxaliplatin, Capecitabine and Bevacizumab as First Line Treatment for Patients With Advanced Colorectal Cancer |
|
|
| Completed | 2 | 63 | US | Oxaliplatin, Eloxatin, Bevacizumab, Avastin, Capecitabine, Xeloda | University of Southern California, Hoffmann-La Roche, Genentech, Inc. | Colorectal Cancer | 06/09 | 03/13 | | |
|
NCT00508872: Folfox-B Study for Patients With Colorectal Liver Metastases |
|
|
| Terminated | 2 | 2 | US | 5-Fluorouracil, 5-FU, Adrucil, Efudex, Bevacizumab, Avastin, Anti-VEGF monoclonal antibody, rhuMAb-VEGF, Leucovorin, Citrovorum, Wellcovorin, Oxaliplatin, Eloxatin | M.D. Anderson Cancer Center, Sanofi | Colorectal Liver Metastases | 06/09 | 06/09 | | |
MK-7454-003, NCT00551213: A Study to Determine the Activity of Robatumumab (SCH 717454, MK-7454) in Participants With Relapsed or Recurrent Colorectal Cancer (P04721, ) |
|
|
| Completed | 2 | 67 | NA | Robatumumab, Irinotecan, Cetuximab, Capecitabine, FOLFOX, CAPEOX/XELOX, FOLFIRI | Merck Sharp & Dohme LLC | Colorectal Cancer | 06/09 | 06/09 | | |
NCT00327119: Phase 2 Study of ABX-EGF (Panitumumab) in Japanese Subjects With M-colorectal Cancer |
|
|
| Completed | 2 | 50 | Japan | ABX-EGF (panitumumab) | Amgen | Metastatic Colorectal Cancer | | | | |
NCT00354887: Capecitabine and Oxaliplatin in Adenocarcinoma of the Small Bowel and Ampulla of Vater |
|
|
| Completed | 2 | 31 | US | Capecitabine, Xeloda, Oxaliplatin, Eloxatin | M.D. Anderson Cancer Center, Sanofi-Synthelabo | Gastrointestinal Cancer | 11/09 | 11/09 | | |
| Completed | 2 | 44 | Europe | IMC-11F8 (necitumumab), Necitumumab, IMC-11F8, LY3012211, Portrazza®, Oxaliplatin, Folinic acid (FA), 5-FU | Eli Lilly and Company | Metastatic Colorectal Cancer | 01/10 | 10/10 | | |
NCT00559455: Phase II Study of Eloxatin+5-FU/LV in Patients With Unresectable Hepatocellular Carcinoma |
|
|
| Completed | 2 | 38 | RoW | Oxaliplatin, Fluorouracil, Leucovorin | Sanofi | Carcinoma, Hepatocellular | 01/10 | 01/10 | | |
NCT00601198: A Study of Amifostine (Ethyol) in Patients With Colorectal Cancer |
|
|
| Terminated | 2 | 4 | US | Amifostine, Flurouracil (5-FU), Leucovorin calcium (LV), Oxaliplatin, Bevacizumab | University of Cincinnati, MedImmune LLC, AstraZeneca | Colorectal Cancer | 01/10 | 01/10 | | |
NCT00483405: Oxaliplatin, Capecitabine, and Cetuximab in Treating Patients With Advanced Liver Cancer |
|
|
| Completed | 2 | 33 | US | cetuximab, Erbitux, capecitabine, Xeloda, oxaliplatin, Eloxatin | UNC Lineberger Comprehensive Cancer Center, Sanofi, Roche Pharma AG, Bristol-Myers Squibb, National Center for Research Resources (NCRR), National Cancer Institute (NCI) | Liver Cancer | 02/10 | 12/10 | | |
|
NCT00761241: Borderline Resectable Pancreatic Cancer: Gemcitabine/Docetaxel and Oxaliplatin Based Chemo/RT |
|
|
| Completed | 2 | 40 | US | Gemcitabine, Docetaxel, 5FU, Oxaliplatin, Alpha-interferon, Abdominal/pelvic radiation therapy, Pancreaticoduodenectomy | Benaroya Research Institute, Sanofi | Pancreatic Cancer | 03/10 | 04/10 | | |
| Completed | 2 | 275 | US, Europe, RoW | Docetaxel + Oxaliplatin, Docetaxel + Oxaliplatin + 5-FU, Docetaxel + Oxaliplatin + Capecitabine | Sanofi | Stomach Neoplasms | 04/10 | 04/10 | | |
NCT01135498 / 2005-004662-16: A Study of Avastin (Bevacizumab) in Combination With Xelox and Tarceva in Patients With Metastatic Colorectal Cancer. |
|
|
| Completed | 2 | 90 | Europe | bevacizumab [Avastin], eloxatin, capecitabine [Xeloda], erlotinib [Tarceva] | Hoffmann-La Roche | Colorectal Cancer | 04/10 | 04/10 | | |
| Completed | 2 | 14 | Europe | Mangafodipir, Teslascan; ACT code V08CAE05, Placebo treatment (0.9% NaCl) | Egetis Therapeutics | Chemotherapy, Colon Cancer | 04/10 | 04/10 | | |
NCT00525005: Docetaxel, Oxaliplatin and S-1 (DOS) for Advanced Gastric Cancer |
|
|
| Completed | 2 | 44 | RoW | DOS (Docetaxel, Oxaliplatin and S-1), Taxotere, Eloxatin, TS-1 | Hallym University Medical Center, Asan Medical Center, Sanofi | Stomach Neoplasms | 06/10 | 06/10 | | |
NCT01159171 / 2005-001012-41: A Study of Avastin (Bevacizumab) and Oxaliplatin Plus Xeloda (Capecitabine) in Patients With Advanced Colorectal Cancer. |
|
|
| Completed | 2 | 50 | Europe | bevacizumab [Avastin], capecitabine [Xeloda], oxaliplatin | Hoffmann-La Roche | Colorectal Cancer | 07/10 | 07/10 | | |
NCT00454636 / 2006-004512-43: A Study of Xeloda (Capecitabine) in Combination With Chemotherapy in Patients With Advanced and/or Metastatic Gastric Cancer. |
|
|
| Completed | 2 | 158 | Europe | Cisplatin, Capecitabine, Xeloda, Epirubicin, Oxaliplatin, Docetaxel | Hoffmann-La Roche | Gastric Cancer | 07/10 | 07/10 | | |
NCT00421824 / 2005-005149-20: Study of Neoadjuvant Chemotherapeutic Treatment (XELOX) Followed by Chemoradiotherapy (XELOX/RT) and Surgery Versus Chemoradiotherapy Followed by Surgery and Chemotherapy in Patients With High Risk Rectal Cancer |
|
|
| Completed | 2 | 108 | Europe | Oxaliplatin, capecitabine, Radiotherapy | Sanofi | Rectal Neoplasms | 11/10 | 11/10 | | |
NCT00436241: A Study of Xeloda (Capecitabine) as First-Line Chemotherapy in Patients With Advanced or Metastatic Gastric Cancer. |
|
|
| Completed | 2 | 45 | RoW | Oxaliplatin, capecitabine [Xeloda] | Hoffmann-La Roche | Gastric Cancer | 11/10 | 11/10 | | |
NCT00127036: Trial for Microarray Analysis of Colon Cancer Outcome-A (MACCO-A) |
|
|
| Terminated | 2 | 65 | US | XELOX, Oxaliplatin and Capecitabine, XELIRI, Irinotecan and Capecitabine, Bevacizumab, Avastin® | H. Lee Moffitt Cancer Center and Research Institute, Roche Pharma AG | Adenocarcinoma, Colon Cancer | 12/10 | 12/10 | | |
NCT01022541 / 2005-004505-29: Capecitabine and Oxaliplatin Plus Bevacizumab as Neoadjuvant Treatment for Untreated Unresectable Liver-only Metastases From Colorectal Cancer |
|
|
| Completed | 2 | 47 | Europe | Capecitabine, Xeloda, Oxaliplatin, Eloxatin, Bevacizumab, Avastin, Liver metastasectomy | Royal Marsden NHS Foundation Trust, Roche Pharma AG | Metastatic Colorectal Cancer | 12/10 | 02/15 | | |
|
|
NCT00636610: A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) With Concurrent Chemotherapy and Bevacizumab As First-Line Therapy for Metastatic Colorectal Cancer |
|
|
| Completed | 2 | 199 | NA | Vismodegib 150 mg, GDC-0449, Erivedge, Placebo to vismodegib, Bevacizumab, Modified FOLFOX, FOLFIRI | Genentech, Inc. | Metastatic Colorectal Cancer | 12/10 | 12/10 | | |
HEARTO, NCT01348412: Hepatic Arterial Chemotherapy With Raltitrexed and Oxaliplatin Versus Standard Chemotherapy in Unresectable Liver Metastases From Colorectal Cancer After Conventional Chemotherapy Failure |
|
|
| Completed | 2 | 31 | Europe | oxaliplatin, raltitrexed, other intravenous chemotherapy drugs | Centre Georges Francois Leclerc, National Cancer Institute, France, Hospira, now a wholly owned subsidiary of Pfizer | Colorectal Cancer, Liver Metastases | 12/10 | 04/18 | | |
NCT00845039: A Study of Irinotecan and Cetuximab With or Without IMC-A12 for Treatment of Participants With Colon or Rectum Cancer Who Got Worse After Their First Treatment With Oxaliplatin and Bevacizumab |
|
|
| Terminated | 2 | 4 | US | Cetuximab, Erbitux, LY2939777, Irinotecan, Camptosar, IMC-A12 (cixutumumab), Cixutumumab, LY3012217 | Eli Lilly and Company, NSABP Foundation Inc | Colon Cancer, Rectal Cancer | 02/11 | 02/11 | | |
NCT00881504: A Study of FOLFOX6 With Bevacizumab for Biliary System Carcinoma |
|
|
| Terminated | 2 | 9 | US | "Bevacizumab" in combination with "modified FOLFOX6"., Avastin, Eloxatin | Georgetown University, Sanofi | Biliary Tract Cancer | 02/11 | 12/11 | | |
NCT00615056 / 2007-006283-30: A Study Combining FOLFOX or FOLFIRI With AG-013736 or Bevacizumab (Avastin) in Patients With Metastatic Colorectal Cancer After Failure Of One First Line Regimen |
|
|
| Completed | 2 | 171 | Japan, US, Canada, Europe, RoW | Bevacizumab (avastin), FOLFIRI (Irinotecan, leucovorin, 5-fluorouracil [5FU]), AG-013736 (axitinib), FOLFOX (oxaliplatin, leucovorin, 5-fluorouracil [5FU]), FOLFIRI (irinotecan, leucovorin, 5-fluorouracil [5FU]) | Pfizer | Colorectal Neoplasms | 03/11 | 04/12 | | |
|
|
APRIORI, NCT01126866: Curative Resectability of Not Optimally Resectable Liver and/or Lung Metastases From Colorectal Carcinoma (CRC) Under Intensified Chemotherapy |
|
|
| Terminated | 2 | 35 | Europe | intensified chemotherapy (FOLFOXIRI/Bevacizumab) | National Center for Tumor Diseases, Heidelberg, Roche Pharma AG, Pfizer | Colorectal Carcinoma | 03/11 | 06/11 | | |
| Completed | 2 | 268 | Europe, RoW | aflibercept, ZALTRAP™, AVE0005, oxaliplatin, 5-FU, Folinic Acid | Sanofi | Colorectal Neoplasms, Neoplasm Metastasis | 04/11 | 01/12 | | |
|
| Completed | 2 | 48 | Canada, Europe | IMC-1121B (ramucirumab), ramucirumab, LY3009806, Oxaliplatin, Folinic acid, 5-FU | Eli Lilly and Company | Colorectal Carcinoma | 04/11 | 08/11 | | |
|
NCT00338039: Induction Cetuximab (IM-C225), Gemcitabine, and Oxaliplatin in Pancreatic Cancer Patients |
|
|
| Completed | 2 | 69 | US | Cetuximab, C225, Erbitux, IMC-C225, Gemcitabine, Gemzar, Gemcitabine Hydrochloride, Oxaliplatin, Eloxatin, Capecitabine, Xeloda, Radiotherapy, XRT | M.D. Anderson Cancer Center, Bristol-Myers Squibb | Pancreatic Cancer | 06/11 | 06/11 | | |
NCT01454180 / 2011-001017-13: Study of Individualized Selection of Chemotherapy in Patients With Advanced Pancreatic Carcinoma According to Therapeutic Targets |
|
|
| Completed | 2 | 31 | Europe | gemcitabine, or gemcitabine and capecitabine, or gemcitabine and erlotinib, or FOLFIRINOX, or FOLFOX, or FOLFIRI., Gemcitabine, Gemcitabine-Capecitabine, Gemcitabine-Erlotinib, FOLFOXIRI, FOLFOX, FOLFIRI | Centro Nacional de Investigaciones Oncologicas CARLOS III, Hospital Universitario de Fuenlabrada, Apices Soluciones S.L., Grupo Hospital de Madrid | Advanced Pancreatic Carcinoma | 10/11 | 12/14 | | |
NCT00700570: A Study of Avastin (Bevacizumab) in Combination With XELOX in Patients With Metastatic Colorectal Cancer |
|
|
| Completed | 2 | 45 | RoW | bevacizumab [Avastin], capecitabine [Xeloda], oxaliplatin | Hoffmann-La Roche | Colorectal Cancer | 11/11 | 11/11 | | |
| Terminated | 2 | 9 | Europe | Oxaliplatin, Capecitabine, Panitumumab, Oxaliplatin, Capecitabine | AIO-Studien-gGmbH, iOMEDICO AG | Colorectal Neoplasms | 11/11 | 03/12 | | |
NCT00585078: Capecitabine and Oxaliplatin in Patients With Advanced or Metastatic Pancreatic Adenocarcinoma |
|
|
| Completed | 2 | 40 | US | Capecitabine, Xeloda, Oxaliplatin, Eloxatin | Beth Israel Deaconess Medical Center, Sanofi | Pancreatic Cancer | 12/11 | 12/11 | | |
NCT00642746: Erlotinib and Chemotherapy for 2nd Line Treatment (Tx) of Metastatic Colorectal Cancer (mCRC) |
|
|
| Terminated | 2 | 16 | US | Erlotinib, Tarceva, Fluorouracil, Leucovorin, Oxaliplatin, Irinotecan | OHSU Knight Cancer Institute, Genentech, Inc., OSI Pharmaceuticals | Metastatic Colorectal Cancer | 12/11 | 12/11 | | |
NCT01077739 / 2009-012090-36: A Study of Avastin (Bevacizumab) With XELOX or FOLFOX in Patients With Metastatic Colorectal Cancer and Disease Progression Under First-line FOLFIRI and Avastin |
|
|
| Completed | 2 | 75 | Europe | fluorouracil (5FU), leucovorin, bevacizumab [Avastin], capecitabine [Xeloda], oxaliplatin | Hoffmann-La Roche | Colorectal Cancer | 01/12 | 01/12 | | |
NCT00177307: Safety and Efficacy Study Using Bevacizumab, Capecitabine and Oxaliplatin for Colorectal Cancer |
|
|
| Completed | 2 | 40 | US | Bevacizumab, Capecitabine 2500 mg/m2/d in two divided doses, (May be 2000 or 3000 mg/m2/d after interim analysis) Days 1-8, every 2 weeks Until disease progression or unacceptable toxicity, Oxaliplatin 85 mg/m2 IV q 2 weekly Until disease progression, unacceptable toxicity,, or Grade 3 neuropathy or cumulative dose of 1200 mg/m2, Capecitabine, Oxaliplatin | University of Pittsburgh, Genentech, Inc. | Cancer | 02/12 | 02/12 | | |
| Withdrawn | 2 | 0 | Canada | irinotecan, capecitabine, oxaliplatin (IXO) and bevacizumab | Ottawa Hospital Research Institute, Hoffmann-La Roche, Sanofi | Metastatic Colorectal Cancer | 02/12 | 02/12 | | |
NCT00721916: Randomized Phase II Study of SOL for Untreated Metastatic Colorectal Cancer |
|
|
| Completed | 2 | 107 | Japan | SOL(The combination therapy of S-1, Leucovorin, and Oxaliplatin), mFOLFOX6(The combination therapy of 5-FU, l-LV and Oxaliplatin) | Taiho Pharmaceutical Co., Ltd., Yakult Honsha Co., LTD | Colorectal Cancer | 03/12 | 05/12 | | |
| Completed | 2 | 54 | US, Europe, RoW | Regorafenib (Stivarga, BAY73-4506), Oxaliplatin, Folinic acid, 5-FU (mFOLFOX6) | Bayer | Colorectal Neoplasms | 03/12 | 06/14 | | |
|
| Completed | 2 | 150 | US | Docetaxel, Taxotere (docetaxel), cetuximab, ERBITUX (cetuximab), oxaliplatin, Eloxatin (oxaliplatin) | US Oncology Research, Eli Lilly and Company, Sanofi | Gastric Cancer Adenocarcinoma Metastatic | 04/12 | 04/12 | | |
|
| Completed | 2 | 150 | Europe | Gemox, Cetuximab | Gustave Roussy, Cancer Campus, Grand Paris, Merck Serono International SA | Advanced Biliary Cancer | 04/12 | 04/12 | | |
|
|
|
NCT00677144: Oxaliplatin and S-1 (OS) Versus Oxaliplatin and Capecitabine (XELOX) for Advanced Colorectal Cancer |
|
|
| Completed | 2 | 88 | RoW | OS (oxalipaltin+S-1), Eloxatin, TS-1, XELOX (oxalipaltin+capecitabine), Xeloda | Hallym University Medical Center, Sanofi | Colorectal Neoplasm | 04/12 | 04/12 | | |
NCT00456599: Study of Gemcitabine and Oxaliplatin With Radiation Therapy in Patients With Pancreatic Cancer |
|
|
| Completed | 2 | 71 | US, Canada | gemcitabine, Gemzar, oxaliplatin, Eloxatin, Radiation, RT | University of Michigan Rogel Cancer Center, Sanofi, Johns Hopkins University, Princess Margaret Hospital, Canada, Ohio State University | Pancreatic Cancer | 05/12 | 01/13 | | |
NCT00707889 / 2007-007081-38: Phase 2 Study of ABT-869 in Combination With mFOLFOX6 Versus Bevacizumab in Combination With mFOLFOX6 to Treat Advanced Colorectal Cancer |
|
|
| Completed | 2 | 159 | US, Canada, Europe, RoW | ABT-869, bevacizumab, oxaliplatin, mFOLFOX6 regimen, folinic acid, fluorouracil | AbbVie (prior sponsor, Abbott), Genentech, Inc. | Advanced Colorectal Cancer, Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum | 05/12 | 05/12 | | |
|
|
NCT00733616 / 2008-001825-32: Efficacy and Safety Study of Combination Therapy With Docetaxel-oxaliplatin-capecitabine in Patients With Advanced Gastric Adenocarcinoma and Intermediate General Status |
|
|
| Completed | 2 | 44 | Europe | DOX: Docetaxel, oxaliplatin, Capecitabine | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD), Sanofi, Hoffmann-La Roche | Gastric Cancer | 05/12 | 05/12 | | |
NCT00816543: Docetaxel + Oxaliplatin + S-1 in Potentially Operable Gastric or Gastroesophageal Adenocarcinoma |
|
|
| Completed | 2 | 41 | RoW | DOCETAXEL, S-1, OXALIPLATIN | Sanofi | Gastric Cancer | 05/12 | 05/12 | | |
| Completed | 2 | 171 | US, Europe, RoW | CT-011, FOLFOX | Medivation, Inc. | Metastatic Colorectal Cancer | 05/12 | 03/13 | | |
|
| Withdrawn | 2 | 0 | Canada | OXALIPLATIN (SR96669), 5-FLUOROURACIL (5-FU), LEUCOVORIN (LV), BEVACIZUMAB | Sanofi | Colorectal Neoplasms | 05/12 | 05/12 | | |
NCT01175291: FOLFOX/Bevacizumab +/- MK-0646 in Metastatic Colorectal Cancer |
|
|
| Withdrawn | 2 | 0 | US | MK-0646, oxaliplatin, leucovorin, 5-FU, Fluorouracil, bevacizumab, Placebo, 5-Fluorouracil | H. Lee Moffitt Cancer Center and Research Institute, Merck Sharp & Dohme LLC | Metastatic Colorectal Cancer | 07/12 | 07/12 | | |
NCT01703910 / 2012-001307-20: Study of Individualized Therapies Selection for Patients With Metastatic Colorectal Carcinoma According to the Therapeutic |
|
|
| Completed | 2 | 29 | Europe | Arm A chemotherapy, Capecitabine, Cisplatin, Cetuximab, Doxorubicin, Fluorouracil, Gemcitabine, Irinotecan, Topotecan, Mitomycin C, Oxaliplatin, Paclitaxel, Docetaxel, Pemetrexed, Raltitrexed, Sorafenib, Erlotinib, Vinorelbine, Dasatinib, Etoposide, arm B chemotherapy | Centro Nacional de Investigaciones Oncologicas CARLOS III, Hospital Universitario de Fuenlabrada, Grupo Hospital de Madrid, Apices Soluciones S.L. | Adenocarcinoma of Colon, Adenocarcinoma of Rectum, Metastatic Disease | 11/12 | 12/14 | | |
NCT01308840: Gemcitabine, Oxaliplatin and Panitumumab in Kras/B-raf Wild-Type Biliary Track and Gallbladder Cancer |
|
|
| Completed | 2 | 31 | US | Panitumumab, GEMOX-Panitumumab (GEMOX-P), oxaliplatin, gemcitabine | University of Rochester, Amgen | Biliary Tract Cancer, Gallbladder Cancer | 01/13 | 01/13 | | |
NCT00525915: Oxaliplatin-Based Chemotherapy and Chemoradiotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Carcinoma |
|
|
| Completed | 2 | 126 | US | 5-Fluorouracil, 5-FU, Adrucil, Efudex, Oxaliplatin, Eloxatin, Radiation Therapy, RT, XRT, Surgery | M.D. Anderson Cancer Center, Sanofi | Esophageal Cancer, Gastroesophageal Cancer | 03/13 | 03/13 | | |
NCT00673673: FOLFOX With Bevacizumab in Metastatic or Unresectable Gastroesophageal and Gastric Cancer |
|
|
| Completed | 2 | 39 | US | FOLFOX, Eloxatin, Fluorouracil, bevacizumab, Avastin | Yale University, Genentech, Inc. | Gastroesophageal Cancer, Gastric Cancer | 05/13 | 07/14 | | |
|
|
| Completed | 2 | 47 | Europe | Cetuximab, Erbitux, Irinotecan, Camptosar, Oxaliplatin, Eloxatin, UFT, Tegafur, Uracil | The Christie NHS Foundation Trust, Merck Sharp & Dohme LLC | Metastatic Colorectal Cancer | 05/13 | 05/13 | | |
|
| Completed | 2 | 76 | US, Europe | Panitumumab, Vectibix, Ganitumab, AMG 479, Irinotecan | Amgen | Metastatic Colorectal Cancer | 07/13 | 07/13 | | |
| Completed | 2 | 25 | Europe | preoperative induction chemotherapy in combination with bevacizumab followed by combined radiochemotherapy with capecitabine, Xeloda (capecitabine), Avastin (bevacizumab), Oxaliplatin | Austrian Breast & Colorectal Cancer Study Group, Hoffmann-La Roche | Rectal Cancer | 08/13 | 08/13 | | |
NCT01246960: A Study of Ramucirumab in Participants With Gastric, Esophageal, and Gastroesophageal Cancer |
|
|
| Completed | 2 | 168 | US | Ramucirumab, LY3009806, IMC-1121B, Placebo, Oxaliplatin, Leucovorin, 5-Fluorouracil, 5-FU | Eli Lilly and Company | Stomach Cancer, Esophageal Cancer | 09/13 | 05/14 | | |
|
NCT01478594 / 2011-003502-24: A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy |
|
|
| Completed | 2 | 265 | US, Canada, Europe, RoW | Tivozanib, AV951, ASP4130, Bevacizumab, Avastin, mFOLFOX6 | AVEO Pharmaceuticals, Inc. | Colorectal Cancer | 09/13 | 01/15 | | |
|
|
|
|
|
|
|
|
| Completed | 2 | 80 | Europe | 5-FU, Irinotecan, Leucovorin, Oxaliplatin, bevacizumab [Avastin] | Hoffmann-La Roche | Colorectal Cancer | 10/13 | 10/13 | | |
|
SETICC, NCT01071655 / 2009-012562-31: Selecting Treatment in Colorectal Cancer:Capecitabine or 5-fluorouracil Selection to be Combined With Oxaliplatin or Irinotecan as First-line Chemotherapy in Advanced Colorectal Cancer |
|
|
| Completed | 2 | 195 | Europe | BVZ+XELOX or BVZ+XELIRI or BVZ+FUIRI or BVZ+FUOX, BVZ+XELOX | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD), Hoffmann-La Roche | Colorectal Cancer | 11/13 | 11/13 | | |
| Completed | 2 | 60 | Europe | Capecitabine, Xeloda, RO 09-1978, Oxaliplatin, treatment defined only by active substance, (no trade name defined; investigators choice) | Austrian Breast & Colorectal Cancer Study Group, Sanofi-Synthelabo, Hoffmann-La Roche | Rectal Cancer | 12/13 | 12/13 | | |
| Completed | 2 | 60 | US | capecitabine (Xeloda), oxaliplatin and bevacizumab (Avastin) | Duke University, Hoffmann-La Roche, Sanofi, Genentech, Inc. | Esophageal Neoplasms, Stomach Neoplasms, Neoplasm Metastasis | 01/14 | 07/14 | | |
|
NCT00959647: A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study |
|
|
| Completed | 2 | 19 | US | Vismodegib, Erivedge, GDC-0449, RO5450815, FOLFOX, FOLFIRI, Bevacizumab, Avastin | Genentech, Inc. | Ovarian Cancer, Basal Cell Carcinoma, Metastatic Colorectal Cancer | 01/14 | 01/14 | | |
NCT01070290 / 2007-004622-25: A Study of ARQ 197 Versus Investigator's Choice of Second-Line Chemotherapy in Patients With Locally Advanced or Metastatic Gastric Cancer Who Have Progressive Neoplastic Disease Following Treatment With One Prior Chemotherapy Regimen |
|
|
| Withdrawn | 2 | 0 | US, Canada, Europe | ARQ 197, Oxaliplatin, capecitabine or irinotecan | ArQule, Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.) | Gastric Cancer | | | | |
| Completed | 2 | 97 | Europe | 5-FU, bevacizumab [Avastin], irinotecan, leucovorin, oxaliplatin | Hoffmann-La Roche | Colorectal Cancer | 02/14 | 02/14 | | |
|
|
NCT01399684 / 2011-001867-28: A Study Evaluating the Efficacy and Safety of MEGF0444A Dosed to Progression in Combination With Bevacizumab and mFOLFOX-6 in Participants With Previously Untreated Metastatic Colorectal Cancer |
|
|
| Completed | 2 | 127 | US, Europe, RoW | 5-Fluorouracil, Bevacizumab, Folinic acid, MEGF0444A, Oxaliplatin, Placebo | Genentech, Inc. | Metastatic Colorectal Cancer | 02/14 | 02/14 | | |
